Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor.

He, Kan; Luettgen, Joseph M; Zhang, Donglu; He, Bing; Grace, James E; Xin, Baomin; Pinto, Donald J P; Wong, Pancras C; Knabb, Robert M; Lam, Patrick Y S; Wexler, Ruth R; Grossman, Scott J

He, Kan; Luettgen, Joseph M; Zhang, Donglu; He, Bing; Grace, James E; Xin, Baomin; Pinto, Donald J P; Wong, Pancras C; Knabb, Robert M; Lam, Patrick Y S; Wexler, Ruth R; Grossman, Scott J.

Affiliation

He K; Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Company, Princeton, NJ, USA.

Eur J Drug Metab Pharmacokinet ; 36(3): 129-39, 2011 Sep.

Article in En | MEDLINE | ID: mdl-21461793

Subject(s)

Anticoagulants/pharmacokinetics; Factor Xa Inhibitors; Pyrazoles/pharmacokinetics; Pyridones/pharmacokinetics; Animals; Blood Proteins/metabolism; Dogs; Humans; Metabolic Clearance Rate; Pan troglodytes; Protein Binding; Pyrazoles/pharmacology; Pyridones/pharmacology; Rats; Species Specificity; Whole Blood Coagulation Time

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrazoles / Pyridones / Factor Xa Inhibitors / Anticoagulants Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Eur J Drug Metab Pharmacokinet Year: 2011 Document type: Article Affiliation country: United States Country of publication: France

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google